semaglutide concerns Weight-loss drugs are becoming more accessible, but are they always safe? Experts raise about the misuse of generics and the risks of unsupervised use. From side effects to long-term impact Specialists discuss concerns over impact

This gradual approach is part of a broader hormone-aware GLP-1 microdosing strategy used during midlife metabolic changes

When GLP-1 patients were compared with those taking DPP4i drugs, the GLP-1 group's recurrence risk was 14.4%, compared with 23.3% in the DPP4i group

That is why side effects often peak during titration and settle down later

The Risks In the use of the SGLT-2s, the sugar doesn't need to be necessarily high, says Trence

As a result, the absence of increased cancer incidence in short-to mid-term follow-up cannot be equated with long-term oncological safety

Thats why the ADA says social determinants of health (SDOH) should be assessed for everyone with diabetes to connect them with available help and resources